IMCD Italy agrees to acquire Selechimica S.R.L.

AMSTERDAM: IMCD N.V., a leading distributor of speciality chemicals and ingredients, announced that IMCD Italy has signed an agreement to acquire 100% of the shares in Selechimica S.R.L., an Italian distributor in the pharmaceutical industry.

Headquartered in Milan, Italy, Selechimica distributes an extensive portfolio of Active Pharmaceutical Ingredients (APIs). With 3 employees, Selechimica represents leading suppliers and generated a revenue of approximately EUR 5 million in the financial year that ended December 31, 2023.

“Selechimica is a valued distributor in the Italian API market. By acquiring Selechimica, IMCD will further strengthen its position in the Italian API market. We are eager to unlock the potential of this acquisition”, comments Marco Madeddu, Managing Director IMCD Italy.

“This transaction provides exciting opportunities for Selechimica. IMCD’s expertise, knowledge of the industry and resources will enable further expansion of the product portfolio and customer base”, says Luca Pesce, Owner of Selechimica.

The closing of the transaction is subject to customary closing conditions and is expected to take place end of June 2024.

MCD N.V. based in Rotterdam, The Netherlands, is a leading global distribution partner and formulator of speciality chemicals and ingredients. IMCD is an expert solutions provider and adds sustainable value to the supply chain. Every day professionals focus on providing the best service through commercial and operational excellence.

The company is mindful of the role they play in creating a better planet for all and formulates with consciousness and executes with care, to address business challenges of tomorrow, in partnership and transparency.

In 2023, with over 4,700 employees, IMCD realised a revenue of EUR 4,443 million. IMCD N.V.’s shares are traded at Euronext, Amsterdam (symbol: IMCD) and included in the Dutch ESG AEX index, as one of 25 companies within the AEX and AMX indices demonstrating best ESG practices.

IMCD Spain to acquire Cobapharma

Leave a Reply

Your email address will not be published. Required fields are marked *